Stem Cells therapy
THE APPLICATION OF STEM CELLS IN THE TREATMENT OF:
- vascular disease of the lower extremities (occlusive disease, diabetic microangiopathy of the lower extremities (diabetic foot), obliterating atherosclerosis of the lower limbs);
- atherosclerotic heart disease, coronary heart disease, myocardial infarction;
- pancreatic necrosis;
- recovery of intervertebral discs;
- trauma and degenerative disease of the cartilage (arthritis, arthrosis);
- restoration of bone defects (false joints);
- Crohn’s disease, ulcerative colitis;
- diabetes types I and II;
- degenerative diseases of the liver (cirrhosis);
- acute renal failure (glomerulonephritis);
- burns (combustiology);
- Reconstructive surgery, aesthetic medicine, cosmetology:
- treatment of vitiligo;
- rejuvenation (anti-aging therapy, anti-agetherapy);
- restore breast shape after partial resection or complete removal of the breast;
- resorption of keloid scars.
1) Induced pluripotent stem cells (also known as iPS cells or iPSCs, IP stem cells ) therapy (1)
2) Embryonic stem cells (ES cells) therapy (2)
3) Autologous stem-cells therapy (3)
4) Allogeneic stem cells therapy (4)
are a type of pluripotent stem cell that can be generated directly from adult cells.
The iPSC technology was pioneered by Shinya Yamanaka’s lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells.
Pluripotent stem cells hold promise in the field of regenerative medicine.
Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.
The most well-known type of pluripotent stem cell is the embryonic stem cell. However, since the generation of embryonic stem cells involves destruction (or at least manipulation) of the pre-implantation stage embryo, there has been much controversy surrounding their use. Further, because embryonic stem cells can only be derived from embryos, it has so far not been feasible to create patient-matched embryonic stem cell lines.
Since iPSCs can be derived directly from adult tissues, they not only bypass the need for embryos, but can be made in a patient-matched manner, which means that each individual could have their own pluripotent stem cell line. These unlimited supplies of autologous cells could be used to generate transplants without the risk of immune rejection.
2) Embryonic stem cells (ES cells)
are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage pre-implantation embryo.
Human embryos reach the blastocyst stage 4–5 days post fertilization, at which time they consist of 50–150 cells.
Isolating the embryoblast or inner cell mass (ICM) results in destruction of the blastocyst, which raises ethical issues, including whether or not embryos at the pre-implantation stage should be considered to have the same moral or legal status as embryos in the post-implantation stage of development.
3) Autologous stem-cell transplantation
(also called autogenous, autogeneic, or autogenic stem-cell transplantation and abbreviated auto-SCT) is autologous transplantation of stem cells—that is, transplantation in which stem cells (undifferentiated cells from which other cell types develop) are removed from a person, stored, and later given back to that same person.
Although it is most frequently performed with hematopoietic stem cells (precursors of blood-forming cells) in hematopoietic stem cell transplantation, cardiac cells have also been used successfully to repair damage caused by heart attacks
4) Allogeneic stem cells
In an allogeneic transplant, stem cells are collected from a matching donor and transplanted into the patient to suppress the disease and restore the patient’s immune system. An allogeneic stem cell transplant is different from an autologous stem cell transplant, which uses stem cellsfrom the patient’s own body.
Induced pluripotent stem cells,iPSCs,Embryonic stem cells,Autologous stem-cells,Allogeneic stem cells therapy